Ionis Pharmaceuticals, Inc. (IONS) Institutional Ownership & Insider Trading

512 institutions reported holding Ionis Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 141 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

IONSIonis Pharmaceuticals, Inc.Follow IONS — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 7.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 27 Oct, in 3 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

512 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +4.0%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	512	180	+4.0%	181	51	148	34
Mar 26	487	173	-0.1%	160	50	146	52
Dec 25	487	176	+4.2%	157	81	128	28
Sep 25	425	168	-0.1%	115	94	112	30
Jun 25	360	169	+1.3%	108	70	100	48
Mar 25	338	166	+4.5%	96	44	110	54
Dec 24	348	160	+1.6%	109	35	107	41
Sep 24	347	156	+8.5%	121	39	97	40

Ionis Pharmaceuticals, Inc. — questions

Who owns Ionis Pharmaceuticals, Inc. stock?: 512 institutions reported Ionis Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: FMR LLC (14.8%), Capital World Investors (13.0%), BlackRock, Inc. (6.4%).
Are Ionis Pharmaceuticals, Inc. insiders buying or selling?: 141 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Ionis Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.